Cannabis firm Organigram's Q3 revenue beats estimates
I'm PortAI, I can summarize articles.
Organigram's fiscal Q3 net revenue rose 72% year-over-year, surpassing analyst expectations with C$70.79 million against a C$68 million estimate. Adjusted EBITDA grew 64%, driven by the Motif Labs acquisition and a 208% increase in international sales. The company is expanding its U.S. presence and anticipates improved gross margins and sustained profitability. Analysts maintain a "buy" rating, with a median 12-month price target of C$2.75, reflecting a 19.3% upside from its recent closing price of C$2.22.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments